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Original Article
Crosstalk between astrocytic CXCL12 and
microglial CXCR4 contributes to the
development of neuropathic pain
Xin Luo, PhD1,2, Wai L Tai, MPhil1,2, Liting Sun, PhD1,2,
Zhiqiang Pan, PhD3, Zhengyuan Xia, PhD1,4, Sookja K Chung,
PhD2,4,5 and Chi Wai Cheung, MD1,4,5
Abstract
Background: Chemokine axis chemokine C-X-C motif ligand 12/C-X-C chemokine receptor type 4 (CXCL12/CXCR4) is
an emerging pain modulator, but mechanisms for its involvement in neuropathic pain remain unclear. Here, we aimed to study
whether CXCL12/CXCR4 axis modulated the development of neuropathic pain via glial mechanisms. In this study, two
mouse models of neuropathic pain, namely partial sciatic nerve ligation (pSNL) model and chronic post-ischemia pain (CPIP)
model, were used.
Results: In the dorsal horn of L3–L5 segment of spinal cord, CXCL12 and CXCR4 were expressed in both astrocyte and
microglia in normal mice. In the pSNL or CPIP model, the expression level of CXCL12 in the ipsilateral L3–L5 segment of
mice spinal cord was increased in an astrocyte-dependent manner on post-operative day (POD) 3. Intrathecal administration
of CXCL12 with AMD3100 (CXCR4 antagonist) or minocycline (microglia activation inhibitor), but not fluorocitrate (astro-
cyte activation inhibitor), reversed CXCL12-indued mechanical allodynia in naı¨ve mice. In these models, AMD3100 and
AMD3465 (CXCR4 antagonist), administered daily from 1 h before surgery and up to POD 3, attenuated the development of
mechanical allodynia. Moreover, AMD3100 administered daily from 1 h before surgery and up to POD 3 downregulated
mRNA levels of tumor necrosis factor alpha, interleukin 1b, and interleukin 6 in the ipsilateral L3–L5 segment of spinal cord
in the pSNL and CPIP models on POD 3.
Conclusion: This study demonstrates the crosstalk between astrocytic CXCL12 and microglial CXCR4 in the pathogenesis
of neuropathic pain using pSNL and CPIP models. Our results offer insights for the future research on CXCL12/CXCR4 axis
and neuropathic pain therapy.
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Background
Pathological pain is a disease caused by abnormal
processing in the nervous system under various patho-
logical conditions, which lasts for more than three
months clinically.1 Neuropathic pain is induced by the
lesion or the disease in the somatosensory nervous
system and is the major subtype of pathological pain.2
Central mechanisms contribute to the chroniﬁcation of
pain and have been taken as the target in the research of
pathological pain, especially neuropathic pain.1,3
Mounting studies indicate that spinal glial cells (astro-
cyte and microglia) are activated in animal models of
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neuropathic pain4 and in patients suﬀering from chronic
pain.5,6 Then, these reactive glial cells release cytokines
and chemokines, which contribute to the neuroinﬂam-
mation and the central mechanisms of neuropathic
pain.7 Chemokines are small and secreted proteins
which include four subfamilies (C-C, C-X-C, X-C, and
C-X3-C).8 Chemokines bind to chemokine receptors that
belong to G-protein-coupled receptor (GPCR) family to
exert the biology function.9 Nowadays, increasing body
of preclinical evidence suggests chemokine axis, such as
chemokine C-C motif ligand 2/C-C chemokine receptor
type 2 (CCL2/CCR2) axis and chemokine (C-X3-C
motif) ligand 1 (CX3CL1)/C-X3-C chemokine receptor
type 1 (CX3CR1) axis,10–13 as the novel neuromodulator
in the pain perception.
Chemokine C-X-C motif ligand 12 (CXCL12) belongs
to C-X-C subfamily of chemokine and is the ligand of C-
X-C chemokine receptor type 4 (CXCR4). CXCL12/
CXCR4 axis widely exists in the central nerve system
(CNS) and serves multiple functions, from ‘‘well-
known’’ migration regulation to ‘‘newly found’’ neuro-
modulation.14 Knowledge from CXCL12 and CXCR4
knockout mice would be the best way for us to under-
stand the role of CXCL12/CXCR4 axis in pathological
pain. However, animals with the deﬁciency of CXCL12
or CXCR4 could not survive due to the abnormal tissue
development.15 The distribution of CXCL12/CXCR4
axis on the nociceptive structure and its pro-nociceptive
property indicates the involvement of this chemokine
axis in the pain perception. CXCL12/CXCR4 axis is dis-
tributed in diﬀerent components in the nociceptor at the
peripheral nervous system, such as dorsal root ganglion
neuron, satellite glia, and Schwann cell,16–18 and at the
CNS, such as neuron, astrocyte, and microglia.16,19,20
Furthermore, CXCL12 peptide has been shown to
induce mechanical allodynia by peripheral18 and by cen-
tral administration.16,19 Moreover, CXCL12/CXCR4
axis was proved to function in the peripheral processing
of pathological pain as shown in animal models of dia-
betes disease, sciatic nerve injury, and acquired immune
deﬁciency syndrome.17,18,21–23 Recently, the role of
CXCL12/CXCR4 axis in central mechanisms of patho-
logical pain raised a growing concern.11 For example,
central CXCL12/CXCR4 axis contributed to the patho-
genesis of opioid tolerance.24 Moreover, the spinal
blockade of CXCL12/CXCR4 axis showed analgesic
eﬀects in animal models of sciatic nerve injury25 and
bone cancer pain.19,26,27
Nowadays, CXCL12/CXCR4 axis has been con-
sidered an emerging pain modulator;28 however, the
common mechanisms accounting for roles of CXCL12/
CXCR4 axis in various pathological pain states, espe-
cially neuropathic pain, remain unclear. As the glial
mechanism is the common mechanism for neuropathic
pain,1 we hypothesized that the glial–glial crosstalk may
account for the involvement of CXCL12/CXCR4 axis in
a wide range of neuropathic pain conditions. To verify
this, the roles of CXCL12/CXCR4 axis in the central
mechanisms were explored in two diﬀerent mouse
models of neuropathic pain, with partial sciatic nerve
ligation (pSNL) to induce peripheral neuropathic pain
(PNP)29 and chronic post-ischemia pain (CPIP) as a
model for complex regional pain syndrome (CRPS).30
Methods
Animals
Animal experiments in this study were approved by the
Committee on the Use of Live Animals in Teaching and
Research and performed according to the guidelines for
the care and use of laboratory animals as established by
the Laboratory Animal Unit at the University of Hong
Kong. The experiments were conducted using adult male
C57BL/6 wild-type mice (25–30 g). Animals were housed
at 23 3C, with humidity ranges between 25% and
45% under a 12-h light/12-h dark cycle (lights on at
07:00). The mice were oﬀered free access to water and
food. They were fed with Lab Diet 5012 (1.0% calcium,
0.5% phosphorus, and 3.3 IU/g of vitamin D3).
pSNL model
The pSNLmodel is an animal model of PNP.29Mice were
anesthetized with the inhalation anesthesia by isoﬂurane
in O2. Under aseptic conditions, the right sciatic nerve was
exposed by an incision from the right sciatic notch to the
distal thigh. By using the femoral head as a landmark, the
location of the sciatic nerve ligation was identiﬁed.
Approximately half of the sciatic nerve was tightly ligated
with a 7-0 silk suture. The incision was closed with 5-0
cotton suture and disinfected with ethanol. As the control
treatments, the right sciatic nerve of sham-operated mice
was only exposed, but not ligated. Furthermore, time
after the operation was counted, when the nerve was
ligated. The ﬁrst day after the surgery was counted as
post-operative day 1 (POD 1).
CPIP model
In the CPIP model, ischemia-and-reperfusion injury
(CPIP injury) caused the edema and mechanical allody-
nia in the mice hindpaw.31 As the symptoms usually
occur in the distal part of the aﬀected limb in CRPS
patients, the CPIP model was developed and used to
study the pathology of CRPS-1.30 Animals were anesthe-
tized with the inhalation anesthesia by isoﬂurane in O2.
After the induction of anesthesia, Durometer O-rings
(O-rings West) were placed around the mice’s right hind-
limbs just proximal to the ankle joint and caused the
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CPIP injury to ipsilateral hindpaws. As the control treat-
ments, sham-operated mice were only anesthetized, but
not placed by O-rings. These rings were removed 3 h later
to induce the reperfusion. Furthermore, time after the
operation was counted, when O-ring was removed. The
ﬁrst day after the surgery was counted as POD 1.
Study drugs
Rat CXCL12 peptide (Genscript) and two CXCR4
antagonists, AMD3100 (Sigma) and AMD3465
(Tocris), were prepared in saline on the day of the
experiment. Recombinant tumor necrosis factor alpha
(TNF-a) from Genscript was used. Astrocyte activation
inhibitor ﬂuorocitrate (Sigma) and microglia activation
inhibitor minocycline (Sigma) were prepared in 1%
dimethyl sulfoxide (DMSO) on the day of the experi-
ment. Saline or 1% DMSO was taken as vehicle controls
in this study.
Cell culture
DI TNC1 astrocyte cell line, derived from rat dienceph-
alon type I astrocyte in a day 1 neonate, was used.32
These cells were maintained with Dulbecco’s modiﬁed
Eagle’s medium (Gibco) supplemented with 10% (v/v)
fetal bovine serum (Invitrogen) and 1% (v/v) penicillin/
streptomycin (P/S) (Invitrogen) at 37C with 5% CO2.
Astrocytes (1 105 cells/ml) were plated on six-well cul-
ture plate and treated with the medium (control) or
TNF-a (10, 100 ng/ml) for 24 h.
Intrathecal injection
A single dose of the intrathecal injection was performed
following previous protocol.33 Before the injection, mice
were anesthetized by gaseous anesthesia with isoﬂurane
and O2 as mentioned above. Using a microliter syringe
(Hamilton) with a 30-gauge needle (BD), a spinal cord
puncture was made to deliver a total volume of 5 ml of
drug(s) to the subarachnoid space between the L3 and L5
levels. Successful administration was indicated by a tail
conﬁguration of the ‘‘S’’ type or tail swinging immedi-
ately after the administration.
von Frey test
Paw withdrawal threshold (PWT) of mice was assessed
by von Frey test, and the same protocol was used in our
previous research.34 Before the experiments, the mice
were placed in a transparent plastic dome with a metal
mesh ﬂoor for nearly 30min. PWT was measured with a
series of von Frey ﬁlaments (IITC). These ﬁlaments were
applied perpendicularly to the plantar surface of mice
hindpaws, with suﬃcient force to bend the ﬁlaments
into an ‘‘S’’ shape. Licking of the paw or quick with-
drawal was considered as a positive response.
Immunohistochemistry
Mice were deeply anesthetized with sodium pentobar-
bital and perfused with ice-cold 0.9% saline, followed
by 4% paraformaldehyde in 0.1M phosphate buﬀer via
the cardiovascular system. The ipsilateral and contralat-
eral L3–L5 spinal cord tissues were collected and post-
ﬁxed in 4% paraformaldehyde and then dehydrated
overnight in 25% sucrose at 4C. The tissue samples
were frozen in tissue freezing medium (Jung) and sliced
transversely at 15 mm, using a cryostat (Leica). The
sections were blocked with 10% normal goat serum in
phosphate-buﬀered saline (PBS) containing 0.1% Triton
X-100 (PBST) at room temperature for 2 h and incu-
bated with antibody(s), including CXCL12 (1:100,
Abcam, #25117), CXCR4 (1:100, Abcam, #2074), glial
ﬁbrillary acidic protein (GFAP; 1:250, Abcam, #10062),
and ionized calcium binding adaptor molecule 1 (IBA1;
1:100, Abcam, #15690), at 4C overnight. After washing
with PBS, sections were incubated for 2 h with secondary
antibody conjugated with Alexa Fluor 488 or/and 568
(Abcam) and followed by nuclear staining using DAPI
(Vector). The immunoreactivity in these sections was
detected with a confocal microscope LSM 710 (Zeiss),
and the immunoﬂuorescent images were analyzed by
Image-Pro Plus (Media Cybernetics).
Rotarod test
To assess the potential side eﬀects of treatments in this
study, a rotarod test was conducted to measure the
motor coordination and balance of the mice.35 Animals
were habituated to the rotarod apparatus (IITC) for two
consecutive days at low-speed rotation (5 r/min) for 600 s
each day before basal measurement. Mice that could not
stay on the rod for 600 s were excluded from this experi-
ment. During the experiment, the animals were tested in
three accelerating trials of 300 s with the rotarod speed
increasing from 5 to 40 r/min over ﬁrst 120 s. There was
an inter-trial interval of at least 20min between each trial
for the same mouse. The falling latency of mice was rec-
orded for each trial with a cutoﬀ time at 300 s.
Real-time polymerase chain reaction
After being euthanized with pentobarbital, both ipsilat-
eral and contralateral L3–L5 segments of spinal cord
were quickly removed from mice and stored at 80C
until RNA extraction. These spinal cord segments were
homogenized in 1ml of ice-cold RNAiso Plus (Takara),
and total mRNA was extracted following the manufac-
turer’s protocol. The quality and quantity of extracted
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RNA were determined with GeneQuant spectrophotom-
eter (Pharmacia). cDNA library was prepared by the
reverse transcription using 2 mg of the extracted total
mRNA with the reverse transcriptase (Life
Technologies). Then, these cDNA samples were diluted
and stored at 20C until further tests. Real-time poly-
merase chain reaction (PCR) test was performed using
Taqman chemistry method (Life Technologies), and the
probes of targets, including TNF-a, interleukin 6 (IL-6),
IL-1b, substance P (SP), calcitonin gene-related peptide
(CGRP), prodynorphin (PDYN), and b-actin (as inter-
nal reference; Life Technologies), were used in this study.
Statistical analysis
The data were expressed as meansSEM. Results from
the immunohistochemical work and the real-time PCR
test (on the samples from in vitro work) were tested using
one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test. Two-way ANOVA followed by
Tukey’s post hoc test were used to analyze data from
the von Frey test, the rotarod test, and the real-time
PCR test (on the samples from in vivo work). A p
value< 0.05 was considered to be statistically signiﬁcant
in this study.
Results
Mechanical allodynia developed in the pSNL
and CPIP models
In this study, the ipsilateral hindpaws of pSNL-injured
mice showed decrease in the PWT from POD 1 to POD
21 in the pSNL model (p< 0.001, n¼ 6, Figure 1(a)).
In CPIP-injured mice, the ipsilateral PWT was decreased
from POD 2 to POD 21 comparing to that of POD 7
(p< 0.05, n¼ 6, Figure 1(b)). However, it was increased
on POD 21 (p< 0.001). Moreover, CPIP-injured mice
showed transient edema in the ipsilateral hindpaws
from 1h to POD1 (p< 0.001, n¼ 5, data not shown).
Expression and distribution of CXCL12/CXCR4 axis
in the lumbar spinal cord of mice
Next, we used immunoﬂuorescence co-staining to inves-
tigate whether CXCL12 and CXCR4 were co-expressed
in glia cell of spinal cord of naı¨ve mice. We found that
CXCL12 and CXCR4 were co-expressed with GFAP
and IBA1, indicating CXCL12 and CXCR4 were
expressed in both astrocyte and microglial cells of
spinal cord (Figure 2).
Expression pattern of CXCL12 in the lumbar spinal
cord in the pSNL and CPIP models
The expression pattern of CXCL12 axis in the spinal
cord has not been reported in the pSNL or CPIP
model. To explore this, animals were divided into
three groups (sham group, pSNL POD 3 group, and
CPIP POD 3 group, n¼ 3 in each group), which
received sham, pSNL, and CPIP surgery, respectively.
Then, the spinal cord tissues were harvested on POD 3
for the immunohistochemical study. In the ipsilateral
lumbar spinal cord dorsal horn, the spinal expression
of GFAP was increased on POD 3 in both pSNL and
CPIP models (p< 0.05, Figure 3(a) and (b)). The
expression of CXCL12 was also increased in the ipsi-
lateral spinal cord dorsal horn of mice receiving the
Figure 1. Mechanical allodynia developed in pSNL- or CPIP-injured mice. The PWTof mice was decreased in the pSNL model (a) and the
CPIP model (b) as determined by the von Frey test. Results are means SEM (n¼ 5–6). ***p< 0.001 and *p< 0.05 versus the baseline and
###p< 0.001 versus data on POD 7 from the same group.
pSNL: partial sciatic nerve ligation; CPIP: chronic post-ischemia pain; PWT: paw withdrawal threshold; POD: post-operative day.
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pSNL or CPIP surgery, comparing to that in sham-
operated mice (p< 0.05, Figure 3(a) and (c)).
Moreover, CXCL12 was mainly co-localized with
GFAP in both models (Figure 3(a)). As the spinal
expression of TNF-a was increased in the pSNL and
CPIP models as mentioned below, TNF-a was applied
to induce the pathological insult in vitro in the current
study (n¼ 4 in each group). Our results showed that
TNF-a increased mRNA levels of CXCL12 in astro-
cyte in a dose-dependent manner (p< 0.001,
Figure 3(d)). However, there was no any change in
the expression of CXCR4 at the ipsilateral lumbar
spinal cord among mice receiving pSNL, CPIP, or
sham operation (data not shown).
Figure 2. Expression and distribution of CXCL12/CXCR4 axis in L3–L5 segment of spinal cord in normal mice. In the spinal cord dorsal
horn, CXCL12 (green) and CXCR4 (green) were co-expressed with IBA1 (red) and GFAP (red). High-resolution images were shown in
boxes, the co-expression was marked with arrows, and nuclear was marked with blue (original magnification: 200, scale bar¼ 100mm).
CXCL12/CXCR4: chemokine C-X-C motif ligand 12/C-X-C chemokine receptor type 4; GFAP: glial fibrillary acidic protein; IBA1: ionized
calcium binding adaptor molecule 1.
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Cellular mechanisms accounting for CXCL12/
CXCR4-mediated nociception in naı¨ve mice
As CXCR4 was expressed in microglia and astrocyte as
mentioned above, the cellular targets of astrocytic
CXCL12 in the neuropathic pain were further assessed.
Minocycline is a selective inhibitor of the microglial acti-
vation, whereas ﬂuorocitrate is a selective inhibitor of the
astrocytic activation at a relatively low concentration.36
These two glial activation inhibitors were found to
account for the analgesic eﬀects in various neuropathic
pain models,37 and they were thus used in this study.
Normal mice were randomly divided into ﬁve groups,
and the pain behavioral responses (PWT) of these mice
were assessed by the von Frey test. In these groups, mice
received a single intrathecal injection of (1) CXCL12 rat
Figure 3. Expression pattern of CXCL12 in ipsilateral L3–L5 segment of spinal cord in the pSNL or CPIP model. (a) The immunor-
eactivity of GFAP (red) and CXCL12 (green) were increased in the ipsilateral lumbar spinal cord of pSNL-injured and CPIP-injured mice on
POD 3, which was summarized in (b) and (c). Original magnification: 200 for all the confocal images (Bar¼ 100 mm). (d) TNF-a increased
the mRNA levels of CXCL12 in astrocyte in vitro. Results are means SEM (n¼ 3). ***p< 0.001, **p< 0.01 and *p< 0.05 versus sham
group. ###p< 0.001 versus TNF-a 0 ng group.
CXCL12: chemokine C-X-C motif ligand 12; GFAP: glial fibrillary acidic protein; pSNL: partial sciatic nerve ligation; CPIP: chronic post-
ischemia pain; POD: post-operative day; TNF-a: tumor necrosis factor alpha.
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peptide (250 ng, n¼ 6), (2) CXCL12 rat peptide (250 ng)
and AMD3100 (5 mg) (n¼ 6), (3) CXCL12 rat peptide
(250 ng) and minocycline (15 mg), (4) CXCL12 rat pep-
tide (250 ng) and ﬂuorocitrate (2 mg), and (5) 1% DMSO
as the vehicle control (n¼ 6). As shown in Figure 2, the
intrathecal delivery of 1% DMSO did not inﬂuence PWT
in normal mice (p> 0.05). A single intrathecal injection
of rat CXCL12 peptide (250 ng) decreased PWT from 1h
to one day after the treatment (p< 0.05), comparing to
the baseline. The co-administration of CXCL12 peptide
(250 ng) and AMD3100 (5 mg) also did not aﬀect PWT in
normal mice as compared to the baseline (p> 0.05).
Similarly, the intrathecal administration of CXCL12
(250 ng) and minocycline (15 mg) did not aﬀected the
PWT. In contrast, the intrathecal administration of
CXCL12 (250 ng) with ﬂuorocitrate (2 mg) decreased
PWT from 1h to one day after the injection in normal
mice (p< 0.05), comparing to the baseline (Figure 4).
Effects of intrathecal CXCR4 antagonists on
motor function in naı¨ve mice
AMD3100 and AMD3465 are CXCR4-speciﬁc antagon-
ists. AMD3465 exhibited nearly 10-fold aﬃnity to
CXCR4, comparing to AMD3100.38 To explore the
eﬀects of these reagents on the motor function, normal
mice were randomly divided into three groups. The study
drugs were given intrathecally, and motor function was
assessed by the rotarod test then. Animals respectively
received intrathecal AMD3100 (10mg, n¼ 6), AMD3465
(10 mg, n¼ 6), and saline (control, n¼ 6) for four days
consecutively. Comparing to the control treatment, the
intrathecal injection of AMD3100 or AMD3465 did not
aﬀect the falling latency (p> 0.05) (Figure 5).
Effects of intrathecal AMD3100 or AMD3465
on the development of mechanical allodynia
in the pSNL model
The eﬀects of intrathecal CXCR4 antagonists on mech-
anical allodynia in pSNL-injured mice were assessed by
the von Frey test. Animals were randomly divided into
three groups before receiving the study drugs and the
von Frey test. In these groups, mice received a single
intrathecal injection of AMD3100 (10mg, n¼ 10),
AMD3465 (10 mg, n¼ 7), or saline (vehicle, n¼ 6) daily
from 1 h before the surgery and up to POD 3. Following
the pSNL surgery, mice from the three groups exhibited
decrease in the PWT from POD 1 to POD 14 (p< 0.001).
Comparing to control group, intrathecal AMD3100
Figure 4. Cellular mechanisms accounting for CXCL12/CXCR4 axis-mediated nociception in naı¨ve mice. The co-treatment of CXCL12
with AMD3100 and minocycline, but not fluorocitrate, prevented CXCL12-induced mechanical allodynia. Results are means SEM (n¼ 6–
8). ***p and ###p< 0.001, *p< 0.05 versus the baseline.
CXCL12/CXCR4: chemokine C-X-C motif ligand 12/C-X-C chemokine receptor type 4; DMSO: dimethyl sulfoxide.
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increased the ipsilateral PWT from POD 1 to POD 6
(p< 0.001) and intrathecal AMD3465 increased the ipsi-
lateral PWT from POD 1 to POD 4 (p< 0.05, Figure
6(a)). The pSNL surgery or the intrathecal treatment of
AMD3100 or AMD3465 did not aﬀect the contralateral
PWT (Figure 6(b)).
Effects of intrathecal AMD3100 on the spinal
production of pain molecules in the pSNL model
The molecular mechanisms accounting for the anti-allo-
dynia eﬀects of CXCR4 antagonism on the development
of PNP remain unclear. Therefore, we studied the eﬀects
of intrathecal AMD3100 on the spinal production of
pain-related molecules in the pSNL models. After
pSNL-injured mice had been received intrathecal
AMD3100 (n¼ 8) or saline (n¼ 6) daily from 1h
before the surgery and up to POD 3, both ipsilateral
and contralateral L3–L5 segments of spinal cord tissue
were harvested on POD 3, and the mRNA levels of pain
molecules were assessed by real-time PCR test. In saline
group, the unilateral sciatic nerve injury increased the
mRNA levels of TNF-a, IL-6, SP, CGRP, and PDYN
(p< 0.05), but did not increase the mRNA levels of IL-
1b, in the ipsilateral lumbar spinal cord as compared to
their contralateral levels (p> 0.05). Comparing to the
control group, intrathecal AMD3100 decreased the ipsi-
lateral levels of TNF-a and IL-6 (p< 0.05) and increased
the contralateral levels of PDYN in pSNL-injured mice
(p< 0.05, Figure 7).
Effects of intrathecal AMD3100 or AMD3465
on the development of mechanical allodynia
in the CPIP model
The behavioral eﬀects after intrathecal CXCR4 antagon-
ists were also studied in the CPIP model. Normal mice
were randomly divided into three groups. In these three
groups, animals received a single intrathecal injection of
AMD3100 (10 mg, n¼ 9), AMD3465 (10mg, n¼ 8), or
saline as the vehicle (n¼ 6) daily from 1h before the
surgery and up to POD 3. Animals from control group
showed decrease in the PWT from POD 2 to POD 14
(p< 0.001). Mice receiving intrathecal AMD3100 also
showed decrease in the ipsilateral PWT from POD 4 to
POD 14 (p< 0.001). Comparing to control group, intra-
thecal AMD3100 progressively and signiﬁcantly
increased ipsilateral PWT on POD 3 and 4 (p< 0.05).
Mice receiving intrathecal AMD3465 exhibited
decreased ipsilateral PWT from POD 5 to POD 14
(p< 0.001). Comparing to the control group, intrathecal
AMD3465 increased the ipsilateral PWT on POD 4
(p< 0.001, Figure 8(a)). Moreover, CPIP injury or the
intrathecal treatment of AMD3100 or AMD3465 did not
aﬀect the contralateral PWT (Figure 8(b)). These results
indicated that central CXCL12/CXCR4 blockade also
Figure 5. Effects of intrathecal injection of two CXCR4 antagonists on motor function in naı¨ve mice. The falling latency of mice were not
affected by intrathecal AMD3100, AMD3465, or saline. Results are means SEM (n¼ 5–6).
CXCR4: C-X-C chemokine receptor type 4.
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Figure 6. Effects of intrathecal AMD3100 or AMD3465 on the development of mechanical allodynia in the pSNL model. The PWT of
pSNL-injured mice was increased by intrathecal AMD3100 and AMD3465 in the ipsilateral (a) but not the contralateral (b) hindpaws as
compared to the saline group. Results are means SEM (n¼ 6–10). ***p, ###p, and cccp< 0.001 and #p< 0.05 versus the baseline. aaap and
bbbp< 0.001, bbp< 0.01 and bp< 0.05 versus the saline group.
pSNL: partial sciatic nerve ligation; POD: post-operative day; PWT: paw withdrawal threshold.
Figure 7. Effects of intrathecal AMD3100 on the spinal production of pain molecules in the pSNL model. After pSNL-injured mice
receiving the intrathecal injection of AMD3100 (n¼ 8) or saline (n¼ 6), the lumbar spinal cord tissue was harvested on POD 3, and pain
molecule levels were assessed by the real-time PCR test, including pro-inflammatory cytokines (a) and neuropeptides (b). Results are
means SEM (n¼ 6–8). ###p< 0.001, aap< 0.01, ap< 0.05 versus the contralateral data in the saline group. bp< 0.05 versus the contra-
lateral data in AMD3100 group. *p< 0.05 versus the ipsilateral data in the saline group.
TNF-a: tumor necrosis factor alpha; IL-6: interleukin 6; IL-1b: interleukin 1-beta; pSNL: partial sciatic nerve ligation; POD: post-operative
day.
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attenuated the development of mechanical allodynia in
the CPIP model.
Effects of intrathecal AMD3100 on the spinal
production of pain molecules in the CPIP model
The molecular mechanisms for intrathecal AMD3100 in
pain were also studied in the CPIP model. After having
received intrathecal injections of AMD3100 (10mg,
n¼ 8) or saline (n¼ 6) for four consecutive days, both
ipsilateral and contralateral L3–L5 segments of spinal
cord were harvested from the CPIP-injured mice on
POD 3, and the levels of pain molecules were assessed
by the real-time PCR test. In saline group, CPIP injury
increased the ipsilateral levels of TNF-a, IL-6, IL-1b, SP,
and PYDN (p< 0.05) and decreased the ipsilateral level
of CGRP, comparing to their contralateral levels
(p< 0.05, Figure 9). Comparing to saline group, intra-
thecal AMD3100 decreased the ipsilateral levels of TNF-
a, IL-6, and IL-1b (p< 0.05) and the contralateral level
of CGRP (p< 0.05, Figure 9).
Discussion
In the present study, two diﬀerent types of neuropathic
pain models were used. The pSNL model is a classic PNP
model.29 In this model, pSNL-injured animals showed
pain behavioral signs of patients with causalgia, and the
mechanical allodynia induced in these animals lasted for
weeks. The mechanisms accounting for CRPS are not
fully understood, but neuropathy is considered as an
essential factor in the pathogenesis of CRPS.39 The
CPIP model has been developed as an animal model of
CRPS type 1.30 In the CPIP model, the ischemia-and-
reperfusion injury caused the transient edema and mech-
anical allodynia, two important features of CRPS type 1.
In the current study, it was found that CXCL12 and
CXCR4 were expressed in astrocyte and microglia.
Therefore, it is highly possible that CXCL12/CXCR4
axis might be involved in the central mechanisms of
pain through the glial–glial (astrocyte–astrocyte, micro-
glia–microglia, or/and astrocyte–microglia) crosstalk.
With the use of these two neuropathic pain models, we
aimed to explore whether CXCL12/CXCR4 axis would
be involved in the communication between glial cells and
would contribute to the development of neuropathic pain.
In the pSNL or CPIP model, the spinal expression of
GFAP was increased following the surgery. Spinal
astrocyte is activated under various neuropathic pain
conditions which contribute to the persistent pain by
releasing cytokines and chemokines.40 Therefore, react-
ive astrocyte might contribute to the central mechanisms
for pain hypersensitivity in the pSNL or CPIP model. In
these two models, the spinal expression of CXCL12 was
increased and mainly expressed in reactive astrocyte on
POD 3, an early stage of persistent pain. Furthermore,
the expression pattern of CXCL12 in astrocyte was fur-
ther substantiated by our in vitro study results.
Previously, it was reported that CXCL12 was expressed
in an astrocyte-dependent way in a bone cancer pain
model, which was reversed by the intrathecal administra-
tion of the astrocyte inhibitor ﬂuorocitrate.19 Our results
also supported that the spinal level of CXCL12 was
increased in an astrocyte-dependent manner under vari-
ous neuropathic pain conditions. In normal mice, intra-
thecal AMD3100 reversed CXCL12-induced mechanical
allodynia, which conﬁrmed the pro-nociceptive proper-
ties of central CXCL12/CXCR4 axis.16,19,26 It was
Figure 8. Effects of intrathecal AMD3100 or AMD3465 on the development of mechanical allodynia in the CPIP model. The PWTof CPIP
mice was increased by intrathecal AMD3100 and AMD3465 in the ipsilateral (a) but not the contralateral (b) hindpaws as compared to the
saline group. Results are means SEM (n¼ 6–10). Results are means SEM (n¼ 6–9). ***p, ###p, and cccp< 0.001 and **p< 0.01 versus
the baseline. bbbp< 0.001, aap< 0.01, and ap< 0.05 versus the saline group.
CPIP: chronic post-ischemia pain; POD: post-operative day; PWT: paw withdrawal threshold.
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further showed that intrathecal minocycline, but not
ﬂuorocitrate, attenuated CXCL12-induced allodynia,
which implicated that microglial CXCR4 might play a
major role in CXCL12-induced allodynia. Moreover, the
intrathecal intervention with two CXCR4 antagonists,
AMD3100 and AMD3465, delayed the development of
chronic pain without impairing the motor function.
Spinal blockade of CXCL12/CXCR4 axis signaling was
reported to attenuate pain hypersensitivity in a PNP
model25 and a bone cancer pain.19 Taken together, our
immunohistochemical and pharmacological evidence
uncovered the cellular and molecular pattern of
CXCL12/CXCR4 axis-mediated glial crosstalk in the
pSNL and CPIP models.
Intracellular elements downstream to GPCR modu-
late gene transcription through a signaling-dependent
manner.41 Since CXCR4 belongs to GPCR family, we
thus evaluated whether the levels of pain molecules were
regulated by central CXCL12/CXCR4 axis in neuro-
pathic pain. TNF-a, IL-6, and IL-1b represented an
important group of pro-inﬂammatory pain mediators,
and they were mainly released by spinal microglia in
the development of neuropathic pain.4,42,43 It has been
found that pro-inﬂammatory cytokines contribute to the
synaptic plasticity44 and the glial–glial interaction45
under diﬀerent neuropathic pain conditions. In this
study, spinal level of TNF-a and IL-6 is upregulated in
the pSNL model, which is in line with their contributive
role in the pain processing and consistent with previous
ﬁndings in a model of peripheral neuropathy.46 The
expression pattern of spinal cytokines in the CPIP
model has not been reported before, and we ﬁrst found
that the levels of TNF-a, IL-6, and IL-1b were increased
in the ipsilateral lumbar spinal cord by the CPIP injury.
In a model of sciatic nerve injury, pharmacological
evidence has shown that microglia contributed to
Figure 9. Effects of intrathecal AMD3100 on the spinal production of pain molecules in the CPIP model. After IR-injured mice receiving
the intrathecal injection of AMD3100 (n¼ 8) or saline (n¼ 6), the lumbar spinal cord tissue was harvested on POD 3, and the levels of pain
molecules were assessed by real-time PCR test, including pro-inflammatory cytokines (a) and neuropeptides (b). Results are means SEM
(n¼ 6–8). #p< 0.05 and ap< 0.05 versus the contralateral data in the saline group. bp< 0.05 versus the contralateral data in AMD3100
group. *p< 0.05 versus the ipsilateral data in the saline group.
TNF-a: tumor necrosis factor alpha; IL-6: interleukin 6; IL-1b: interleukin 1-beta; CPIP: chronic post-ischemia pain; SP: substance P; CGRP:
calcitonin gene-related peptide; PDYN: prodynorphin; IR: ischemia-and-reperfusion.
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the development of pain hypersensitivity and neuroin-
ﬂammation.47 Previously, it was shown that CXCL12/
CXCR4 axis modulates the production of proinﬂamma-
tory cytokines (TNF-a and IL-6) in microglia
in vitro.45,48 Here, our results ﬁrst showed that the
spinal blockade of CXCL12/CXCR4 axis downregulated
levels of these pro-inﬂammatory cytokines in both the
pSNL and CPIP models. Taken together, our results
demonstrated the crosstalk between astrocytic CXCL12
and microglial CXCR4, which might contribute to pain
hypersensitivity via modulating the neuroinﬂammation
in the pSNL and CPIP models.
Among pain neuropeptides, SP was essential to the
pain signal transduction at the lumbar spinal cord,
while CGRP facilitated SP-mediated pain signaling.49
Our results showed that the spinal level of SP was
increased in two neuropathic pain models whereas that
of CGRP levels was only increased in the pSNL model.
Such diﬀerence in the expression pattern of CGRP and
SP might represent the diﬀerence in the central mechan-
isms between PNP and CRPS potentially. Even
CXCL12/CXCR4 axis was co-localized with SP and
CGRP in rat spinal cord,16 we could not ﬁnd that the
spinal blockade of CXCL12/CXCR4 axis aﬀect the levels
of SP and CGRP at the ipsilateral spinal cord in both
models. These ﬁndings implicated that CXCL12/CXCR4
axis might not modulate SP or CGRP-mediated pain
signaling in the pathogenesis of neuropathic pain. In
both pSNL and CPIP models, we found that the ipsilat-
eral level of PDYN was increased on POD 3. PDYN-
containing neurons are widely distributed on the pain-
related brain areas, and PDYN-derived peptides
promote the abnormal pain perception.50 Here, our
results ﬁrst showed the involvement of PDYN in the
Figure 10. Proposed mechanisms for CXCL12/CXCR4 axis in the pathogenesis of pain hypersensitivity in the pSNL or CPIP model.
pSNL injury or CPIP injury might facilitate the increase of CXCL12 in the spinal cord dorsal horn through an astrocyte-dependent manner.
By binding to microglial CXCR4, CXCL12 might increase the production of pro-inflammatory cytokines in microglia and contribute to the
development of neuropathic pain.
CXCL12/CXCR4: chemokine C-X-C motif ligand 12/C-X-C chemokine receptor type 4; CPIP: chronic post-ischemia pain; pSNL: partial
sciatic nerve ligation; TNF-a: tumor necrosis factor alpha; IL-1b: interleukin 1-beta; IL-6: interleukin 6.
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spinal cord in neuropathic pain development. The cross-
talk between chemokine and opioid system has been con-
sidered as an emerging target for chronic pain therapy.51
However, it was found that spinal level of PDYN was
not aﬀected by AMD3100 in the pSNL or CPIP model,
suggesting that CXCL12/CXCR4 axis may not interact
with PDYN at least in the current experimental settings.
Additionally, our results also showed that other pain
molecules might not contribute to CXCL12/CXCR4
axis-mediated pain processing in the pSNL or CPIP
model, including proopiomelanocortin, proenkephalin,50
endothelin-1, endothelin receptor A, endothelin receptor
B,32,34,52 intercellular adhesive molecules-1, and vascular
cell adhesive molecules-153 (data not shown).
Based on the results presented in the current study,
the mechanisms for central CXCL12/CXCR4 axis in the
development of pain hypersensitivity in the pSNL or
CPIP model are proposed at Figure 10. pSNL or CPIP
injury leads to the increase of CXCL12 in the spinal
dorsal horn through an astrocyte-dependent manner.
By binding to microglial CXCR4, CXCL12 increases
the production of pro-inﬂammatory cytokines in micro-
glia, which contributes to the development of pain hyper-
sensitivity. In this study, we found that CXCL12/
CXCR4 axis contributed to the development of the neu-
roinﬂammation and pain hypersensitivity in two neuro-
pathic pain models.
In conclusion, our study demonstrates that CXCL12
is mainly expressed in astrocyte, while CXCR4 in both
astrocyte and microglia in the mouse spinal cord. In the
pSNL or CPIP model, the spinal expression of CXCL12
is upregulated in an astrocyte-dependent manner at the
early stage of the development of neuropathic pain. It is
further found that intrathecal CXCL12 induces mechan-
ical allodynia via microglial CXCR4. In both pSNL and
CPIP models, the spinal blockade of CXCL12/CXCR4
axis delays the development of mechanical allodynia and
neuroinﬂammation. This study suggests that the cross-
talk between astrocytic CXCL12 and microglial CXCR4
is involved in the pathogenesis of neuropathic pain
hypersensitivity using the pSNL and CPIP models. Our
results provide new insights for the future research on
CXCL12/CXCR4 axis and neuropathic pain.
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